New pill aims to plug protein leak in kidney patients
NCT ID NCT07614477
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgA nephropathy) that cause protein to leak into urine. Participants take the drug twice daily for a year. The main goal is to see if it safely reduces protein levels and helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EVER001 (oral capsule, 200 mg twice daily)
What this could lead to
If successful, EVER001 could offer a new treatment option for people with certain kidney diseases, potentially reducing protein leakage and preserving kidney function.
What could go wrong
This is an early-phase study with only 45 participants, so results may not apply to everyone. The drug may cause side effects or fail to improve kidney health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••